I'm LongbridgeAI, I can summarize articles.Greenwich Lifesciences rose 10.23% in after-hours trading; Moderna fell 0.71% in after-hours trading, with a transaction volume of $1.17 million; Natera fell 0.34% in after-hours trading, with a transaction volume of $72,300; CollPlant Biotech fell 9.49% in after-hours trading, with a transaction volume of $36,500
U.S. Stock Night Market Movements
Greenwich Lifesciences rose 10.23% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Stocks with High Trading Volume in the Industry
Moderna fell 0.71% in the night market. Based on recent news,
-
On August 29, BioNTech announced the termination of its phase II clinical trial for the colorectal cancer mRNA vaccine, leading to a loss of confidence in mRNA vaccines, causing Moderna's stock price to drop by 6.6%;
-
On August 29, Wall Street analysts upgraded Moderna's rating to Buy, with a target price of $180, driving the stock price up;
-
On August 31, positive news emerged regarding the melanoma vaccine co-developed by Moderna and Merck, with the stock price surging approximately 150% this month. Biotech stocks have shown volatility recently, and investors should be cautious.
Natera fell 0.34% in the night market. There is no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news
CollPlant Biotech fell 9.49% in the night market. Based on recent key news:
-
On August 31, CollPlant announced the acquisition of the Israeli deep tech company LightSolver, expanding into the supercomputing and photonic computing markets. This move, through equity financing including prepaid shares and milestone warrants, led to stock price volatility. Source: SEC announcement
-
On August 29, CollPlant's financial situation worsened, with GAAP revenue for the first quarter nearly disappearing at only $73,000, and net losses widening to $3.1 million. The market reacted strongly to its failure to meet Nasdaq's minimum bid notification, causing the stock price to drop. Source: Zhitong Finance
-
On August 31, LightSolver's technology entered the commercial validation phase, collaborating with major partners like Boeing, driving CollPlant's new growth trajectory in high-performance computing. This news impacted the stock price. Source: Wall Street Insight The biotech industry is facing financial pressure, and market volatility has intensified